Interaction Review

Good morning, Dr. Brooks. Thank you for making time. I understand you had some questions about Veloratine's cardiovascular outcome data from the VELOCITY-CV substudy.

Yes, James. I'm a heart failure specialist, and several of my hypertension colleagues have been asking about Veloratine. I want to understand the cardiovascular outcomes beyond just blood pressure reduction.

Great question. The VELOCITY-CV substudy enrolled 1,200 patients with treatment-resistant hypertension and at least one additional cardiovascular risk factor. The primary composite endpoint of cardiovascular death, MI, and stroke showed a hazard ratio of 0.78 favoring Veloratine, with a 95% confidence interval of 0.62 to 0.98.

That's a significant result. Was it powered for each individual component of the composite?

The study was only powered for the composite endpoint. The individual components trended favorably but did not reach statistical significance independently. The strongest signal was for stroke reduction with a hazard ratio of 0.71, but again, this was a secondary analysis.

What about patients with existing heart failure? I have patients with HFpEF who also have resistant hypertension.

That's actually a very exciting area. Based on the mechanism of action, we believe Veloratine could have direct cardioprotective effects beyond blood pressure lowering that may benefit HFpEF patients. The vasodilatory and anti-fibrotic properties suggest potential for ventricular remodeling benefits.

Is there any clinical data in heart failure patients specifically?

There's currently a Phase II trial, VELOCITY-HF, that's enrolling HFpEF patients. We don't have results yet, but the pre-clinical data was very encouraging. In the VELOCITY-CV substudy, the small subset of patients with concurrent HFpEF did show improvement in NT-proBNP levels, though this was an exploratory post-hoc analysis.

I'd be interested in seeing that post-hoc data. Can you share the publication?

The cardiovascular outcomes data was published in the New England Journal last year. I'll send you the full publication along with the supplementary appendix that includes the HFpEF subgroup analysis.

What about drug interactions? Many of my heart failure patients are on complex regimens with multiple medications.

Veloratine is metabolized via CYP3A4, so there are potential interactions with strong CYP3A4 inhibitors like ketoconazole and clarithromycin. It's important to avoid those combinations. With common cardiac medications like beta-blockers, ACE inhibitors, and statins, no clinically significant interactions have been observed in the drug interaction studies.

Good to know. I'll review the NEJM paper and the substudy data. Can we schedule a follow-up once the VELOCITY-HF interim results are available?

Absolutely. I expect interim data around mid-year. I'll reach out as soon as the results are disclosed. Thank you for your interest in the cardiovascular outcomes story, Dr. Brooks.